Implantica Unveils Promising Two-Year Study Results of RefluxStop

Innovative Advances in GERD Treatment with RefluxStop

Implantica AG, a pioneering medtech company, has recently shared exciting findings from an independent study examining the RefluxStop implantable device for the treatment of gastroesophageal reflux disease (GERD). This innovative device has shown promising results, with over 90% improvement in the quality of life for GERD patients after a two-year follow-up period. The results were presented at a recent conference, drawing significant attention from the medical community.

Study Highlights and Outcomes

The study involved 158 patients and demonstrated impressive effectiveness and safety outcomes. After two years, a remarkable 96.4% of participants were able to discontinue their regular PPI medication, a common treatment for GERD. Furthermore, there was a reported 90.9% improvement in the GERD health-related quality of life (GERD-HRQL) score. Many patients included in the study had complex health conditions, with 22% suffering from large hiatal hernias greater than 3 cm and 44% experiencing active esophagitis.

Leading Surgeons and Their Insights

The data was derived from leading anti-reflux surgeons in Germany, including Dr. Moustafa Elshafei and Dr. Thorsten Lehmann. Their expertise in this study has been invaluable. Dr. Elshafei expressed delight at the outcomes presented, emphasizing the significant interest surrounding the RefluxStop device among UK peers.

Dr. Lehmann's Perspective

Dr. Lehmann articulated how the RefluxStop device could provide surgical solutions to patients with large hiatal hernias, enhancing their treatment options. He has witnessed strong results from the almost 200 patients he has treated with RefluxStop over the past three years.

Implantica's Vision and Commitment

Dr. Peter Forsell, Founder and CEO of Implantica, expressed gratitude towards the surgeons for their contributions in disseminating the study results. He highlighted the significance of GERD as an affliction affecting approximately 9.5 million individuals in the UK. The company is optimistic about expanding the RefluxStop treatment's reach, particularly among NHS centers that are poised to embrace this technology soon.

About the RefluxStop Device

This innovative device is poised to redefine treatment paradigms for GERD. Unlike traditional surgical approaches, which can lead to adverse effects like difficulty swallowing or inability to belch, RefluxStop addresses the root cause of acid reflux without unnecessary pressure on the food passageway. Instead, it helps in restoring the lower esophageal sphincter's natural positioning, facilitating the body's ability to manage acid reflux more effectively.

About Implantica

Implantica AG is committed to advancing medical technology. Their flagship product, RefluxStop™, represents a significant step towards comprehensive anti-reflux treatment, supported by robust clinical trial data. The company is also developing an eHealth platform to monitor health parameters remotely, further enhancing the treatment landscape through innovation.

Frequently Asked Questions

What is the RefluxStop device?

The RefluxStop device is an implantable solution designed for managing gastroesophageal reflux disease (GERD), aiming to provide lasting relief without the side effects typical of conventional surgery.

What were the results of the recent study on the RefluxStop device?

The study reported over 90% improvement in patients' GERD-related quality of life after two years, with a vast majority able to discontinue standard PPI medication.

Who were the key contributors to the study?

Top German anti-reflux surgeons, particularly Dr. Moustafa Elshafei and Dr. Thorsten Lehmann, played crucial roles in conducting and presenting the study findings.

What commitment does Implantica have towards patient care?

Implantica is dedicated to rapidly advancing the availability of the RefluxStop treatment in healthcare settings, especially within the NHS, to serve the substantial population affected by GERD.

How does RefluxStop differ from traditional GERD surgeries?

RefluxStop operates without enduring pressure on the esophagus, restoring the sphincter's natural position, which differs from traditional methods that can cause side effects like swallowing difficulties.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.